Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 15 | 2024 | 416 | 4.770 |
Why?
|
| Opioid-Related Disorders | 9 | 2025 | 260 | 4.240 |
Why?
|
| Buprenorphine | 5 | 2025 | 95 | 2.630 |
Why?
|
| Narcotic Antagonists | 7 | 2025 | 109 | 2.470 |
Why?
|
| Drug Overdose | 4 | 2024 | 66 | 2.390 |
Why?
|
| Opiate Substitution Treatment | 4 | 2025 | 25 | 2.250 |
Why?
|
| Naloxone | 4 | 2024 | 48 | 1.790 |
Why?
|
| Benzodiazepines | 3 | 2024 | 98 | 1.720 |
Why?
|
| Prescription Drug Monitoring Programs | 4 | 2022 | 7 | 1.710 |
Why?
|
| Chronic Pain | 2 | 2024 | 124 | 1.470 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2024 | 728 | 1.120 |
Why?
|
| Pharmacists | 5 | 2023 | 84 | 1.050 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 3424 | 0.990 |
Why?
|
| Drug Prescriptions | 7 | 2024 | 221 | 0.940 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 606 | 0.920 |
Why?
|
| Focus Groups | 2 | 2024 | 198 | 0.920 |
Why?
|
| Methadone | 1 | 2024 | 126 | 0.900 |
Why?
|
| Motivation | 2 | 2023 | 316 | 0.860 |
Why?
|
| Antidepressive Agents | 2 | 2025 | 285 | 0.850 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 136 | 0.830 |
Why?
|
| Pharmacies | 1 | 2022 | 13 | 0.810 |
Why?
|
| Prescription Drugs | 2 | 2020 | 54 | 0.800 |
Why?
|
| Self Efficacy | 1 | 2023 | 195 | 0.780 |
Why?
|
| Prescriptions | 4 | 2023 | 39 | 0.770 |
Why?
|
| Fear | 1 | 2023 | 199 | 0.760 |
Why?
|
| Health Policy | 2 | 2020 | 213 | 0.750 |
Why?
|
| Alcoholism | 1 | 2023 | 231 | 0.710 |
Why?
|
| Social Desirability | 1 | 2020 | 19 | 0.700 |
Why?
|
| Preceptorship | 1 | 2020 | 32 | 0.680 |
Why?
|
| Education, Pharmacy | 1 | 2020 | 55 | 0.650 |
Why?
|
| Health Expenditures | 3 | 2024 | 102 | 0.580 |
Why?
|
| Vaccines | 1 | 2022 | 366 | 0.570 |
Why?
|
| Adult | 17 | 2025 | 29438 | 0.550 |
Why?
|
| Health Risk Behaviors | 1 | 2017 | 7 | 0.550 |
Why?
|
| Texas | 7 | 2024 | 3583 | 0.550 |
Why?
|
| Child Restraint Systems | 1 | 2017 | 6 | 0.550 |
Why?
|
| Community Pharmacy Services | 1 | 2017 | 10 | 0.550 |
Why?
|
| Physicians | 1 | 2023 | 581 | 0.550 |
Why?
|
| Sickness Impact Profile | 1 | 2017 | 36 | 0.550 |
Why?
|
| United States | 11 | 2024 | 10887 | 0.530 |
Why?
|
| Depression | 1 | 2025 | 1218 | 0.530 |
Why?
|
| Humans | 33 | 2025 | 124593 | 0.500 |
Why?
|
| Perception | 1 | 2017 | 218 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.480 |
Why?
|
| Budgets | 1 | 2015 | 17 | 0.480 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 662 | 0.470 |
Why?
|
| Mothers | 1 | 2017 | 351 | 0.440 |
Why?
|
| Melanoma | 3 | 2024 | 834 | 0.410 |
Why?
|
| Middle Aged | 12 | 2025 | 26714 | 0.400 |
Why?
|
| Qualitative Research | 3 | 2024 | 539 | 0.390 |
Why?
|
| Intention | 2 | 2022 | 93 | 0.380 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 442 | 0.360 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2020 | 24 | 0.350 |
Why?
|
| Young Adult | 8 | 2024 | 9014 | 0.340 |
Why?
|
| Female | 17 | 2025 | 66482 | 0.330 |
Why?
|
| Insulin | 1 | 2015 | 1202 | 0.330 |
Why?
|
| Health Care Surveys | 2 | 2023 | 287 | 0.320 |
Why?
|
| Logistic Models | 2 | 2024 | 1805 | 0.310 |
Why?
|
| West Virginia | 2 | 2017 | 7 | 0.280 |
Why?
|
| Male | 12 | 2025 | 61191 | 0.270 |
Why?
|
| Multiple Sclerosis | 2 | 2020 | 329 | 0.270 |
Why?
|
| Pain, Postoperative | 3 | 2024 | 265 | 0.260 |
Why?
|
| Patient Discharge | 3 | 2024 | 489 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1269 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 841 | 0.230 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2876 | 0.220 |
Why?
|
| Help-Seeking Behavior | 1 | 2023 | 2 | 0.220 |
Why?
|
| Nonprescription Drugs | 1 | 2024 | 50 | 0.220 |
Why?
|
| Parents | 2 | 2022 | 1015 | 0.210 |
Why?
|
| Retrospective Studies | 7 | 2025 | 16314 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 124 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2024 | 670 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2024 | 4795 | 0.190 |
Why?
|
| Pain Management | 2 | 2024 | 179 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3694 | 0.180 |
Why?
|
| Faculty, Pharmacy | 1 | 2020 | 6 | 0.180 |
Why?
|
| Cancer Pain | 1 | 2020 | 24 | 0.180 |
Why?
|
| Internet | 1 | 2023 | 375 | 0.170 |
Why?
|
| Electronic Health Records | 2 | 2024 | 722 | 0.170 |
Why?
|
| Self Report | 1 | 2023 | 512 | 0.170 |
Why?
|
| Drug Utilization | 1 | 2020 | 160 | 0.160 |
Why?
|
| Students, Pharmacy | 1 | 2020 | 64 | 0.160 |
Why?
|
| Comorbidity | 1 | 2024 | 1529 | 0.160 |
Why?
|
| Controlled Substances | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 245 | 0.150 |
Why?
|
| Hydrocodone | 1 | 2018 | 35 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 2498 | 0.150 |
Why?
|
| Geriatrics | 1 | 2018 | 73 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 510 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 808 | 0.140 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2017 | 1 | 0.140 |
Why?
|
| Vaccination | 1 | 2022 | 953 | 0.140 |
Why?
|
| Automobiles | 1 | 2017 | 3 | 0.140 |
Why?
|
| Aged | 6 | 2024 | 19703 | 0.130 |
Why?
|
| Pandemics | 2 | 2023 | 1099 | 0.130 |
Why?
|
| Income | 1 | 2017 | 133 | 0.130 |
Why?
|
| Adolescent | 6 | 2024 | 19279 | 0.130 |
Why?
|
| Educational Status | 1 | 2017 | 273 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 398 | 0.120 |
Why?
|
| Rural Population | 1 | 2017 | 256 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2023 | 3441 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12322 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 2771 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2022 | 14009 | 0.070 |
Why?
|
| Child | 2 | 2024 | 24374 | 0.060 |
Why?
|
| Inappropriate Prescribing | 1 | 2024 | 41 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2024 | 19 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2024 | 138 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2023 | 105 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 307 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2024 | 371 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2024 | 375 | 0.040 |
Why?
|
| Students | 1 | 2023 | 248 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 1350 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1280 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 51 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 482 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 171 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 639 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 19 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 671 | 0.040 |
Why?
|
| Risk Factors | 2 | 2024 | 10270 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1424 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 721 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 941 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1322 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 266 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1185 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1777 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6292 | 0.020 |
Why?
|